|
|
Volumn 359, Issue 9315, 2002, Pages 1410-
|
|
Why do COX-2 inhibitors increase risk of cardiovascular events?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
ISOENZYME;
LACTONE;
MEMBRANE PROTEIN;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PROSTAGLANDIN SYNTHASE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
PTGS2 PROTEIN, HUMAN;
ROFECOXIB;
SULFONE;
THROMBOXANE A2;
ANIMAL;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
DRUG ANTAGONISM;
HEART INFARCTION;
HUMAN;
METABOLISM;
MOUSE;
ANIMALS;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITORS;
CYCLOOXYGENASE INHIBITORS;
HUMANS;
ISOENZYMES;
LACTONES;
MEMBRANE PROTEINS;
MICE;
MYOCARDIAL INFARCTION;
NAPROXEN;
PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;
SULFONES;
THROMBOXANE A2;
|
|
EID: 0037140430
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(02)08393-9 Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|
